# Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

> **NCT04293419** · PHASE2 · UNKNOWN · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 58 (estimated)

## Conditions studied

- Rectal Cancer

## Interventions

- **DRUG:** Durvalumab (MEDI4736)

## Key facts

- **NCT ID:** NCT04293419
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12-18
- **Primary completion:** 2024-12-18
- **Final completion:** 2025-03-01
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2021-06-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04293419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04293419, "Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04293419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*